



FIGURE 1




2/16

FIGURE 2


Arrows indicate
use of β_2 agonist




Patient 3




Patient 2



3/16




4/16



5/16


FIGURE 5
DRB1*0405/0408 Restriction of FC1P2 Response
FC1P2 can be presented to 0408 T cells by 0405 but not 0404

a) DRB1*0404 L cells b) DRB1*0405 L cells




Subject: DRB1*0408

6/16




7/16

FIGURE 7



8/16

FIGURE 7



Subject DRB1*0405

9/16

	A	R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W	Y	V	A
1	A	R	N	D	C	Q	E	G	H	I	L	K	M	F	P						
2		R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S					
3			N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T				
4				D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W			
5					C	Q	E	G	H	I	L	K	M	F	P	S	T	W	Y		
6						Q	E	G	H	I	L	K	M	F	P	S	T	W	Y	V	
7							E	G	H	I	L	K	M	F	P	S	T	W	Y	V	A
8								G	H	I	L	K	M	F	P	S	T	W	Y	V	A
9									H	I	L	K	M	F	P	S	T	W	Y	V	A
10										I	L	K	M	F	P	S	T	W	Y	V	A
11											L	K	M	F	P	S	T	W	Y	V	A
12												K	M	F	P	S	T	W	Y	V	A
13													M	F	P	S	T	W	Y	V	A
14														F	P	S	T	W	Y	V	A
15															P	S	T	W	Y	V	A
16																S	T	W	Y	V	A
17																	T	W	Y	V	A
18																		W	Y	V	A
19																			Y	V	A
20																				V	A
21																					A
22																					
23																					
24																					
25																					
26																					
27																					
28																					

Figure 8 (Sheet 1 of 2). Hypothetical protein (top row) and second overlapping

10/16

	R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W	C	L	L	G
1																					
2																					
3																					
4																					
5																					
6																					
7																					
8	R																				
9	R	N																			
10	R	N	D																		
11	R	N	D	C																	
12	R	N	D	C	Q																
13	R	N	D	C	Q	E															
14	R	N	D	C	Q	E	G														
15	R	N	D	C	Q	E	G	H													
16	R	N	D	C	Q	E	G	H	I												
17	R	N	D	C	Q	E	G	H	I	L											
18	R	N	D	C	Q	E	G	H	I	L	K										
19	R	N	D	C	Q	E	G	H	I	L	K	M									
20	R	N	D	C	Q	E	G	H	I	L	K	M	F								
21	R	N	D	C	Q	E	G	H	I	L	K	M	F	P							
22	R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S						
23		N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T					
24			D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W				
25				C	Q	E	G	H	I	L	K	M	F	P	S	T	W	C			
26					Q	E	G	H	I	L	K	M	F	P	S	T	W	C	L		
27						E	G	H	I	L	K	M	F	P	S	T	W	C	L	L	
28							G	H	I	L	K	M	F	P	S	T	W	C	L	L	G

Figure 8 (Sheet 2 of 2). Hypothetical protein (top row) and peptides overlapping by one residue.

11/16

FIGURE Multiple Overlapping Peptides (MOP)

Field 1 Chain

DLFLIGIPDEYVEQVAQVKALPVPYLENARIILKNCVDANKMITEEDKENALSLLDKIYTSPLC (SEQ ID No 4)

DLFLIGT (SEQ ID No 6)

FLTGTPDEYVEQVAQV (SEQ ID No 1)

EQVAQVKALPVPYLENA (SEQ ID No 2)

KALPVPYLENARIILKNCV (SEQ ID No 3)

RIILKNCVDANKMITEEDKE (SEQ ID No 7)

KMITEEDKENALSLLDK (SEQ ID No 8)

KENALSVDKIYTSPL (SEQ ID No 9)

Field 1 Chain

NELLLKLSLTKYNATEPERTAMIKKIQDCYVENGUISRVLDGLVMITISSKDCMGEAVQNTVEDLKLNTLGR (SEQ ID No 5)

SEQ ID No 10)

FL (SEQ ID No 11)

FLLLKLSLTKYNAT (SEQ ID No 12)

LLTKYNATEPERTAMIKK (SEQ ID No 13)


TAMIKKIQDCYVENGII (SEQ ID No 14)

CYVENGUISRVLDGLV (SEQ ID No 15)

SRVLDGLVMITISSSK (SEQ ID No 16)


ISSSKDCMGEAVQNTV (SEQ ID No 17)

AVQNTVEDLKLNTLGR (SEQ ID No 18)




13/16

FIGURE 11




Changes in the cutaneous late phase response to intradermal whole cat dander following intradermal administration of MOP



15/16

Figure 12b



16/16

